• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 1:59:45 PM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMMP alert in real time by email
    SC 13G/A 1 immp-sc13ga_123120.htm AMENDMENT TO FORM SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

    Immutep Limited

    (Name of Issuer)

     

    Sponsored ADS

    (Title of Class of Securities)

     

    45257L108**

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** The CUSIP number is for the American Depository Shares that trade on the NASDAQ Global Market, each representing 100 ordinary shares. No CUSIP number has been assigned to the ordinary shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

    CUSIP No .

    45257L108

     

    Page 2 of 8

     

    1

    NAME OF REPORTING PERSON
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
    (ENTITIES ONLY) EIN: 82-2066653

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United State of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     

    12

    TYPE OF REPORTING PERSON

    IA, PN

     

     

     

     

     

     

     

     
     

    CUSIP No .

    45257L108

     

    Page 3 of 8

     

    1

    NAME OF REPORTING PERSON
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
    (ENTITIES ONLY) EIN:  82-2105101

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     

    12

    TYPE OF REPORTING PERSON

    PN

     

     

     

     

     

     

     

     
     

    CUSIP No .

    45257L108

     

    Page 4 of 8

     

    1

    NAME OF REPORTING PERSON

    Altium Capital Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
    (ENTITIES ONLY) EIN: 82-2086430

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United State of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     

    12

    TYPE OF REPORTING PERSON

    OO

     

     

     

     

     

     

     

     
     

     

    CUSIP No. 45257L108   Page 5 of 8

     

    Item 1(a).   Name of Issuer: Immutep Limited (the “Issuer”)
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices: Level 12, 95 Pitt Street
    Sydney, 2000 New South Wales, Australia
         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP, Altium Capital Management, LLC, and Altium Growth GP, LLC. Altium Growth Fund, LP is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, Altium Growth Fund, LP. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, Altium Growth Fund, LP.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting person is
    152 West 57 Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Sponsored ADS
         
    Item 2(e).   CUSIP Number: 45257L108
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
             

     

     

     

    CUSIP No . 45257L108   Page 6 of 8

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
      As of the close of business on December 31, 2020, each of the Reporting Persons have no beneficial ownership of the Issuer’s Common Stock.

     

     

     

     

     

    CUSIP No . 45257L108   Page 7 of 8

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 10, 2021
         
      Altium Capital Management, LP
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb
      Title: CEO
         
      Altium Growth Fund, LP
       
      By: Altium Growth GP, LLC
      Its: General Partner
         
      Signature: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb
      Title: Managing Member of Altium Growth GP, LLC
         
      Altium Growth GP, LLC
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb
      Title: Managing Member

     

     

     

     

    Page 8 of 8

     

    EXHIBIT INDEX

     

     

    EXHIBIT 1:Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

    Members of Group

     

     

     

     

    Get the next $IMMP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMMP

    DatePrice TargetRatingAnalyst
    5/17/2024$10.00Overweight
    CapitalOne
    8/3/2023$7.00Outperform
    Robert W. Baird
    8/3/2021$8.30Buy
    Ladenburg Thalmann
    7/16/2021$8.00Buy
    Maxim Group
    More analyst ratings

    $IMMP
    SEC Filings

    View All

    SEC Form 6-K filed by Immutep Limited

    6-K - IMMUTEP Ltd (0001506184) (Filer)

    8/6/25 7:14:15 PM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immutep Limited

    6-K - IMMUTEP Ltd (0001506184) (Filer)

    7/30/25 8:39:56 PM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Immutep Limited

    6-K - IMMUTEP Ltd (0001506184) (Filer)

    6/23/25 8:42:02 PM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1

    SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), for first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients who have PD-L1 expression below 1 (Combined Positive Score [CPS] <1). Based on its review of the encouraging data in 1L HNSCC with CPS <1 from the TACTI-003 (KEYNOTE

    8/5/25 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep Quarterly Activities Report Q4 FY25

    Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countriesTrial-in-Progress poster for TACTI-004 presented at the 2025 American Society for Clinical Oncology (ASCO) Annual MeetingNovel combination of efti with KEYTRUDA® (pembrolizumab) and chemotherapy in INSIGHT-003 trial achieves high response rate of 60.8% and 90.2% disease control rate (N=51) in 1L NSCLC In high unmet need patients with TPS <50% (N=47), who represent over two-thirds of 1L NSCLC population, the triple combination with efti achieved a 59.6% response rate as comp

    7/30/25 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

    SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from 6-9 September 2025. The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company's antigen presenting cell (APC) activator, eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrol

    7/29/25 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CapitalOne initiated coverage on Immutep with a new price target

    CapitalOne initiated coverage of Immutep with a rating of Overweight and set a new price target of $10.00

    5/17/24 7:43:01 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Immutep with a new price target

    Robert W. Baird initiated coverage of Immutep with a rating of Outperform and set a new price target of $7.00

    8/3/23 6:20:48 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Immutep with a new price target

    Ladenburg Thalmann initiated coverage of Immutep with a rating of Buy and set a new price target of $8.30

    8/3/21 8:13:45 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMP
    Leadership Updates

    Live Leadership Updates

    View All

    Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

    Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseasesCHDR will utilize its unique challenge model that enables insights into IMP761's pharmacological activity early in clinical developmentTrial expected to begin mid-CY2024 SYDNEY, AUSTRALIA, April 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreem

    4/18/24 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep Selects Charles River Laboratories for IMP761's GLP Toxicology Study

    Media Release Appointment of Charles River Laboratories ("Charles River") to run Immutep's preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to first-in-human trials for this first-in-class LAG-3 agonist antibody designed to treat the underlying cause of multiple autoimmune diseasesCharles River is a highly respected, global provider of drug discovery and non-clinical development solutions operating more than 110 sites across more than 20 countries SYDNEY, AUSTRALIA, May 29, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LA

    5/29/23 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep Quarterly Activities Report

    Media Release Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancerPositive final data reported from patients with 2nd line non-small cell lung cancer refractory to anti-PD-(L)1 therapies, including Overall Survival rate of 39% at 21 monthsRandomised TACTI-003 Phase IIb trial has reached 75% enrolment subsequent to quarter end and top line results anticipated in H2 of CY2023Expansion of INSIGHT-003 evaluating triple combination of efti, pembrolizumab and chemotherapy post encouraging initial safety and efficacy in 1st line non-small cell lung cancerSolid cash pos

    4/27/23 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Immutep Limited (Amendment)

    SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)

    2/9/24 7:59:50 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immutep Limited (Amendment)

    SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)

    2/9/23 7:57:21 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Immutep Limited

    SC 13G - IMMUTEP Ltd (0001506184) (Subject)

    2/9/22 8:58:14 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMP
    Financials

    Live finance-specific insights

    View All

    Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

    Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49%, and ≥50%), differentiates efti in combination with KEYTRUDA® from other chemotherapy-free immuno-oncology combinations in non-small cell lung cancerExceptional durability and quality of responses exhibited through ove

    10/23/23 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep Announces Publication of Abstracts at ESMO Congress 2023

    Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CESTImmutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) SYDNEY, AUSTRALIA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the publication of abstracts with data from the TACTI-002 and INSIGHT-003 trials in 1st line non-small cell lung cancer (1L NSCLC) at t

    10/16/23 8:00:00 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care